Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient.
OBJECTIVE
To determine whether voriconazole dosage adjustment is required during continuous veno-venous haemodiafiltration (CVVHDF).


METHODS
Voriconazole pharmacokinetics were studied in a critically ill patient under CVVHDF. The analysis was carried out for 12 h following a 6 mg/kg dose. Voriconazole concentrations were measured by HPLC in blood inlet and outlet lines and in dialysate.


RESULTS
The total body clearance of voriconazole was 20.3 L/h, with a terminal half-life of 13.7 h and a distribution volume of 399 L. The estimated sieving coefficient was 0.53 and the filtration-dialysis clearance 1.2 L/h.


CONCLUSIONS
CVVHDF does not significantly affect voriconazole disposition and requires no dosage adjustment.
Robatel
C
C
Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, Lausanne, Switzerland.
Rusca
M
M
Padoin
C
C
Marchetti
O
O
Liaudet
L
L
Buclin
T
T
D000368:Aged; D000935:Antifungal Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D002851:Chromatography, High Pressure Liquid; D017809:Fatal Outcome; D005260:Female; D006207:Half-Life; D006440:Hemofiltration; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000188:drug therapy; D011743:Pyrimidines / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012128:Respiratory Distress Syndrome / Q000150:complications / Q000188:drug therapy; D014230:Triazoles / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole